Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2022-03-31T16:31:16Z | - |
dc.date.available | 2022-03-31T16:31:16Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 0258-851X | * |
dc.identifier.other | OAK-31276 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/261036 | - |
dc.description.abstract | Aim: To identify prognostic factors for surgically resected gallbladder cancer (GBC). Patients and Methods: Medical records of 66 patients with GBC undergoing potentially curative resection between 2001 and 2017 were retrospectively reviewed. Results: After a median follow-up of 39.9 months (range=0.5-216.4 months), 22 locoregional recurrences and 25 distant metastases occurred. Adjuvant radiotherapy and adjuvant chemotherapy failed to prove efficacy in all patient groups. In patients with stage III-IV GBC, adjuvant chemotherapy showed a marginally positive effect on locoregional control (p=0.064), and was significantly beneficial for overall survival (p=0.040), and adjuvant treatment improved both locoregional control and overall survival (p=0.029 and p=0.005, respectively). On multivariate analysis, a negative resection margin was a significant prognostic factor for superior local control, and disease-free and overall survival (p=0.003, p=0.010 and p=0.005, respectively) and adjuvant treatment was associated with improved overall survival (p=0.018). Conclusion: Adjuvant treatment is recommended for patients with stage III-IV GBC following curative surgical resection. © 2022 International Institute of Anticancer Research. All rights reserved. | * |
dc.language | English | * |
dc.publisher | International Institute of Anticancer Research | * |
dc.subject | adjuvant chemotherapy | * |
dc.subject | adjuvant radiotherapy | * |
dc.subject | adjuvant treatment | * |
dc.subject | Gallbladder cancer | * |
dc.subject | prognostic factor | * |
dc.title | Role of Adjuvant Treatment in High-risk Patients Following Resection for Gallbladder Cancer | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 36 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 961 | * |
dc.relation.lastpage | 968 | * |
dc.relation.journaltitle | In Vivo | * |
dc.identifier.doi | 10.21873/INVIVO.12787 | * |
dc.identifier.wosid | WOS:000795871700001 | * |
dc.identifier.scopusid | 2-s2.0-85125688302 | * |
dc.author.google | Park Y. | * |
dc.author.google | Kim K. | * |
dc.author.google | Park H.J. | * |
dc.author.google | Chun H.-J. | * |
dc.author.google | Choi D. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240222162403 | * |